表皮生长因子受体表达与突变亚型在非小细胞肺癌中的临床意义  

Clinical significance of epidermal growth factor receptor expression and its subtype mutations in non-small cell lung cancer

作　　者：张竞[1] 王彬[1] 王云喜[1] 王波[1] 初向阳[1] 

机构地区：[1]解放军总医院胸外科,北京100853

出　　处：《实用临床医药杂志》2016年第9期92-96,共5页Journal of Clinical Medicine in Practice

摘　　要：目的探讨非小细胞肺癌(NSCLC)患者表皮生长因子受体(EGFR)基因的mRNA表达水平及EGFR亚型突变情况。方法收集128例NSCLC患者的临床资料,使用液相芯片技术对患者标本的EGFR E18-21基因突变情况和EGFR的mRNA表达水平进行检测。结果本组患者EGFR基因突变率为47.7%,其中E19基因突变率为21.1%,E21基因的突变率为26.6%,无E18及E20基因突变。EGFR E19基因突变与吸烟史呈显著相关性(r=0.238,P<0.01),EGFR E21基因发生突变与肿瘤病理类型(r=-0.213,P<0.05)和肿瘤分化程度(r=-0.190,P<0.05)都呈现相关性。EGFR基因表达水平与肿瘤病理类型相关(r=0.244,P<0.01)。结论 EGFR突变好发于19、21外显子,其中无吸烟史患者易发生E19突变,腺癌及肿瘤分化程度高的患者易发生E21突变。腺癌患者中的EGFR基因表达水平更高。Objective To investigate the mRNA expression of epidermal growth factor receptor（ EGFR） and its subtype mutations in patients with non-small cell lung cancer（ NSCLC）.Methods Clinical materials of 128 NSCLC patients were collected. E18-21 mutations of EGFR and mRNA expression of EGFR in fresh specimens of tumor tissues were detected by liquid chip technology. Results The mutation rate of EGFR gene was 47. 7%,including 21. 1% E19 gene mutation,26. 6% E21 gene mutation,0% E18 and E20 gene mutations. There was a significant correlation between EGFR E19 gene mutation and smoking history（ r = 0. 238,P〈 0. 01）. EGFR E21 gene mutation had correlations with tumor histological type（ r =- 0. 213,P〈 0. 05） and the degree of tumor differentiation（ r =- 0. 190,P〈 0. 05）. EGFR gene expression was associated with tumor type（ r =0. 244,P〈 0. 01）. Conclusion EGFR mutations tend to occur in exons 19 and 21. E19 mutation easily occurs in patents without smoking history and E21 mutation easily occurs in patients with highdifferentiated adenocarcinoma. EGFR gene expression is highly expressed in adenocarcinoma patients.

关 键 词：非小细胞肺癌 靶向治疗 表皮生长因子受体 

分 类 号：R734.2[医药卫生—肿瘤]